Neurocrine Biosciences stock has delivered a 59.0% return over the past five years, yet its current valuation checks still lean on the cheap side rather than pricing in a clear premium. That mix of solid long term performance and a strong value read is what investors now need to weigh.

• Over the past 5 years, Neurocrine Biosciences has returned 59.0%, which puts recent share price moves in the context of a stock that has already created meaningful value for long term holders.
• Fresh data from the KINECT-PRO study publication can support expectations for INGREZZA related revenue, while any setback in clinical, regulatory or competitive trends for its key treatments may weigh on how much investors are willing to pay for future cash flows.
• Across Simply Wall St’s broader checks, Neurocrine Biosciences screens as undervalued on 5 of 6 metrics, which means the valuation work currently leans in favor of the stock being priced below its assessed worth 5/6 score.

The stock’s next move may depend on whether the recent value signals at Neurocrine Biosciences truly reflect an underappreciated earnings and cash flow profile or if the current price already captures most of that story.

Is Neurocrine Biosciences Still Cheap on Earnings?

The P/E ratio is a useful way to see what the market is currently willing to pay for each dollar of Neurocrine Biosciences earnings. For Neurocrine Biosciences, the current P/E is about 22.0x, which is higher than the broader biotech industry average of 17.4x yet far below the peer group average of 59.7x.

On Simply Wall St’s fair multiple framework, a P/E of about 24.9x would be more in line with the company’s profile, so the current 22.0x sits modestly below that mark. Despite the positive attention from the new KINECT PRO study results on INGREZZA, the stock still trades at a discount to this tailored fair multiple, while also avoiding the very high valuations seen in some peers.

Overall, Neurocrine Biosciences stock appears undervalued on its current P/E relative to the fair multiple implied by its fundamentals and sector position.

The Neurocrine Biosciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Neurocrine Biosciences sit on the Community page and act as the bridge between the valuation puzzle above and the specific future that would need to unfold for the stock to be worth materially more or less than today's price. Where a single ratio or model outputs one number, these narratives set out the growth, margin and earnings assumptions behind it so you can monitor whether those assumptions still line up with reality.

One of the top community narratives on Neurocrine Biosciences: 28% undervalued

"A broad, late-stage and diversified CNS pipeline including multiple Phase III programs targeting major depressive disorder and schizophrenia leverages advances in precision medicine and increases visibility for future earnings…"

Do you think there's more to the story for Neurocrine Biosciences? Head over to our Community to see what others are saying!

The Bottom Line

Neurocrine Biosciences screens as undervalued on market multiples, with its current P/E below the tailored fair multiple and well under some peers. That sets up a case where the market is not paying a premium despite the company’s established treatments and pipeline attention. From here, the real swing factor is whether earnings and cash flow from key drugs, including INGREZZA, develop in a way that convinces investors to award a higher multiple or keeps the current discount in place as a reflection of clinical, regulatory and competitive risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.